



DIVISION OF  
CORPORATION FINANCE

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

April 29, 2021

Daniel J. Hicklin, Ph.D.  
President and Chief Executive Officer  
Werewolf Therapeutics, Inc.  
1030 Massachusetts Avenue, Suite 210  
Cambridge, MA 02138

**Re: Werewolf Therapeutics, Inc.  
Registration Statement on Form S-1  
Exhibit No. 10.11  
Filed April 8, 2021  
File No. 333-255132**

Dear Dr. Hicklin:

We have concluded our assessment of your redacted exhibit for compliance with applicable form requirements and will process your supplemental response and related materials in accordance with your request.

Sincerely,

Division of Corporation Finance